Live flu vaccine trial

By Kate McDonald
Friday, 27 February, 2009

Melbourne’s BioDiem and Schering-Plough’s vaccine business unit Nobilon have begun a clinical development program for BioDiem’s intranasal live attenuated influenza vaccine (LAIV).

The vaccine, named SCH 900795, is composed of three attenuated flu viruses that will be delivered in a single-dose intranasal spray.

The Phase I study will test the safety, tolerability and immunogenicity of the vaccine in 120 healthy volunteers.

Noxopharm says paper reveals science behind its immune system platform

Clinical-stage Australian biotech company Noxopharm Limited says a Nature Immunology...

Neurosensing/neurostimulation implants session to be held on Monday

On Monday, a session at UNSW Sydney will include people who are benefiting from bioelectronics...

argenx and Monash University partner against autoimmune diseases

To advance a pioneering molecule for autoimmune diseases, global immunology company argenx has...

Content from other channels on our network

Liquid metal to 'harvest' clean hydrogen from water

Epson makes progress with sustainability plans and initiatives in Australia and New Zealand

Sustainable wastewater treatment achieved for urban areas

'Brownfielding' increases to meet metal demand

NSW to exceed energy storage targets

InterSystems Honoured with Four 2026 Best in KLAS Awards

How do different types of pain influence empathy?

St Vincent's Hospital Sydney junior doctors class action underway

Hospital waiting times remain high, new Productivity Commission data reveals

From vision to vigilance: building a secure digital future for health care

Cyber risk is rising faster than Australian manufacturers can respond

Electric actuation: a gamechanger for upstream processes

Government seeks input on wind and transmission infrastructure

Additive manufacturing unlocks power for space and defence missions

Video-based water detection reduces contamination in gas pipeline